GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2007

Psychogenics and Cephalon Ally on Neuropsychiatric Drug Discovery

  • PsychoGenics entered into a drug discovery agreement with Cephalon related to neuropsychiatric disorders. Cephalon will provide related compounds, while Psycogenics will evaluate these candidates.

    The companies will jointly identify those candidates suitable for clinical development. If either company decides to further develop any of these drugs, that firm will pay the other milestone and royalty fees .

    PsychoGenics' technologies combines in vivo behavioral expertise with robotics, computer vision, and bio/cheminformatics. The platform is used to evaluate potential therapies related to a number of neuropsychiatric disease indications.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?